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Abstract
Background: This study aimed to systematically review and to meta-analyse the accuracy of digital breast
tomosynthesis (DBT) versus digital mammography (DM) in women with mammographically dense breasts in
screening and diagnosis.
Methods: Two independent reviewers identified screening or diagnostic studies reporting at least one of four
outcomes (cancer detection rate-CDR, recall rate, sensitivity and specificity) for DBT and DM in women with
mammographically dense breasts. Study quality was assessed using QUADAS-2. Meta-analysis of CDR and recall rate
used a random effects model. Summary ROC curve summarized sensitivity and specificity.
Results: Sixteen studies were included (five diagnostic; eleven screening). In diagnosis, DBT increased sensitivity
(84%–90%) versus DM alone (69%–86%) but not specificity. DBT improved CDR versus DM alone (RR: 1.16, 95% CI 1.
02–1.31). In screening, DBT + DM increased CDR versus DM alone (RR: 1.33, 95% CI 1.20–1.47 for retrospective
studies; RR: 1.52, 95% CI 1.08–2.11 for prospective studies). Recall rate was significantly reduced by DBT + DM in
retrospective studies (RR: 0.72, 95% CI 0.64–0.80) but not in two prospective studies (RR: 1.12, 95% CI 0.76–1.63).
Conclusion: In women with mammographically dense breasts, DBT+/−DM increased CDR significantly (versus DM)
in screening and diagnosis. In diagnosis, DBT+/−DM increased sensitivity but not specificity. The effect of DBT + DM
on recall rate in screening dense breasts varied between studies.
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Background
Breast cancer (BC) is the most common cancer in women
and the leading cause of cancer death among women in
Europe [1]. Many countries have adopted population-wide
BC screening, initially with film-screen and subsequently
with digital mammography (DM), aiming to lower mortal-
ity from BC by earlier detection of the disease [2, 3]. How-
ever, DM has moderate sensitivity, for which estimates vary
from 67.3% to 93.3% [4]. High breast tissue density, defined
as having more than 50% density on mammography, cat-
egories 3 and 4 or categories c and d in the BI-RADS 4th
or 5th edition respectively [5, 6] reduces the sensitivity of
mammography due to its masking effect, and may increase
false-positives due to superimposition of dense paren-
chyma. It is estimated that about half of all women taking
part in screening have dense breasts although the propor-
tion differs in age-groups [7, 8]. Breast density is also con-
sidered an independent risk factor for BC [9].
Digital Breast Tomosynthesis (DBT) enables pseudo-3D
imaging of the breast, resulting in better discrimination of
tissue structures and potentially improved visualisation of
cancer [10, 11]. Hence, DBT has the potential to improve
both sensitivity and specificity of imaging in BC screening,
leading to more detected cancers with fewer false-
positives [10]. However, using both DM and DBT in-
creases radiation dose to the breast, if both acquisitions
* Correspondence: x.a.phi@umcg.nl
1Department of Epidemiology, University Medical Center Groningen,
Hanzeplein 1, PO Box 30.001, 9700RB Groningen, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Phi et al. BMC Cancer  (2018) 18:380 
https://doi.org/10.1186/s12885-018-4263-3
are obtained. Improved screening accuracy using DBT has
been shown in several prospective and retrospective stud-
ies, in screening populations and in studies using BC-
enriched mammogram series [12, 13]. Very few reviews
have examined the role of DBT in women with dense
breasts, and these were either concise reports or did not
use systematic methodology [14, 15]. Therefore, in this
work we aimed to systematically review the literature on
the accuracy of DBT compared to DM in women with
dense breasts. A secondary objective was to perform a
meta-analysis on four outcomes (cancer detection rate -
CDR, recall rates, sensitivity and specificity) of DBT com-
pared to DM in women with dense breasts.
Methods
A systematic review and meta-analysis were performed
by two independent reviewers (XAP and GHdB or AT),
following a predetermined review protocol based on the
PRISMA guidelines (http://www.prisma-statement.org/)
(Additional file 1). Discordance throughout the process
was discussed between the two reviewers and if consen-
sus was not reached then a third reviewer (GHdB or
NH) was consulted.
We searched for studies that included women older than
18 years, who underwent breast imaging using DBT and
DM and were classified as having dense breasts on mam-
mography. Studies comparing DBT to DM and reporting at
least one accuracy measure were considered. Prospective as
well as retrospective comparative studies could be included.
Data sources and searches
PubMed and the Web of Science were searched for rele-
vant English-language articles published between January
2007 up to and including May 2017. Additionally, refer-
ences of identified eligible articles and reviews were
manually screened for additional relevant sources. The
search strategy included three main key words: Tomo-
synthesis or 3D mammography in the title or abstract
and BC in all fields (see Fig. 1).
Eligibility criteria
Eligible studies were: studies that compared the accuracy
of DBT and DM in a screening setting or diagnostic set-
ting; reported data on at least one of 4 outcomes (CDR,
recall rate, sensitivity and specificity) for both DBT and
DM (where data reported or could be calculated); in-
cluded at least 100 women with dense breasts who were
asymptomatic (screening setting) or recalled after screen-
ing (diagnostic setting); and where ‘dense breast’ was de-
fined as more than 50% density [BI-RADS 3 and 4 (4th
edition) or BI-RADS c and d (5th edition)]. Only English
publications were considered. Studies which did not con-
tain original data, or simulation studies, were excluded. If
multiple publications were based on the same study popu-
lation, the most extensive study in terms of data reported
was chosen.
Study selection
Articles identified from the search were loaded into Ref-
Works (2016, ProQuest LLC) and duplicates were re-
moved. Titles/ abstracts, followed by full text, were
reviewed based on predefined criteria and a final set of
eligible studies were selected.
Data collection process
A predefined form was developed, and used to extract in-
formation from included studies: type of study (prospective
or retrospective), study setting (screening or diagnostic),
number of women with dense breasts, inclusion and exclu-
sion criteria, age of women with dense breast (age of whole
study population if not specified for dense breasts), number
of screening rounds if applicable, length of follow-up,
method of reporting breast density, number of BCs, reading
protocol (single or double reading), definitions for recall
and for positive test, DBT manufacturer, number of DBT
views (one or two), utilisation of additional modalities (DM
or none), and reported outcomes for DBT and for DM in
women with dense breasts (CDR, recall rate sensitivity and/
or specificity).
Risk of bias and quality appraisal
The quality of included studies was assessed using the
QUADAS-2 tool which was modified to ensure assessment
was appropriate for the breast screening or diagnostic con-
text. The domains considered were: patient selection, index
test, reference standard, flow and timing and applicability.
This was performed by two reviewers independently and
final quality assessment was based on consensus.
Data analysis
Meta-analysis was performed to estimate the relative risk of
cancer detection and of recall for DBTand DM using a ran-
dom effects model in RevMan 5.3. This analysis was per-
formed separately for screening and diagnostic studies, and
also separately for studies comparing two groups of women
(unpaired data) and those comparing detection within one
group of women (paired data). Subgroup analyses were car-
ried out to examine the effect of covariates, modality
(whether stand-alone DBT, or DBT with DM), outcome
definitions, and reading protocol (single or double-reading).
A summary ROC was produced for DBTand DM for sensi-
tivity and specificity where studies reported these outcomes.
For computation, it was assumed that all screens were inde-
pendent, even if there were multiple screens for some pa-
tients in some studies. Heterogeneity across studies was
quantified with I2 measure for CDR and recall rate.
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Results
Study inclusion
A total of 608 unique studies were eligible for title and ab-
stract screening, and 63 studies were checked at full-text
reading (details in Fig. 1). Sixteen studies [12, 16–30] met
our predefined inclusion criteria and were included in the
evidence synthesis. The meta-analysis was performed sep-
arately for 5 diagnostic studies, and for 11 screening stud-
ies (these were examined separately for 8 screening
studies that used two independent study groups, and the 3
screening studies that used one study group). Details
about study inclusion with reasons for exclusion are de-
scribed in the flow-chart (Fig. 1).
Overview of included studies
Characteristics of 16 included studies are presented in
Additional file 2. Studies differed in terms of study setting,
threshold definitions, breast density categorization, reading
protocol and whether DBT was used alone or with DM.
Among the five diagnostic studies, four studies using DBT
and DM reported sensitivity and specificity [12, 18, 21, 30]
and one study reported recall rate [17]. It was possible to
calculate CDR from three studies which reported sensitivity
and specificity [12, 18, 21]. All but two of 11 screening
studies performed one screening round. Nine screening
studies reported CDR [16, 19, 20, 23–27, 29] and nine stud-
ies reported recall rate [16, 19, 20, 22, 24, 26–29].
Quality assessment
Six of the 16 included studies were at high risk of bias in
terms of patient selection. In five studies, DBT was per-
formed more often in women with dense breast, with family
history of BC or it was performed based on availability and
women’s preferences [20, 22, 27–29]. Three studies did not
Fig. 1 Flow-chart of study inclusion
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specify density classification [22, 26, 28]. Three of 16 studies
were at high risk of bias in terms of index test due to un-
specified outcome definition [26, 28, 29].. One study did not
specify the reference standard for negative images [21]. One
third of the studies were at high risk of bias regarding flow
and timing domain because DBT and DM were performed
in different periods of time [24–27, 29]. Overview of risk of
bias and applicability is shown in Table 1.
Comparing tomosynthesis and digital mammography in
women with dense breasts in diagnostic settings (N = 5)
In the diagnostic setting, sensitivity of DBT ranged from 84%
(95% CI 71–93) [30] to 89% (95% CI 81–95) [12], being
higher than the sensitivity of DM which ranged from 69%
(95% CI 58–79) [12] to 86% (95% CI 81–89) [21] (Fig. 2).
The specificity of DBT ranged from 72% (95% CI 68–72)
[21] to 93% (95% CI 89–96) [18] and was not different from
the specificity of DM which ranged from 57% (95% CI 55–
59) [21] to 94% (95% CI 91–97) [18] (Fig. 2). Using DBT
with or without DM improved CDR with a ratio of 1.12
(95% CI 1.01–1.24) compared to DM alone (Fig. 3a). Hetero-
geneity across studies was small (I2 = 8%). Only one study
reported a significant reduction in recall rate using DBT plus
DM compared to DM alone (RR = 0.56, 95% CI 0.47–0.66)
[17]. Due to the small number of studies (n= 5), subgroup
analysis was not performed.
Comparing tomosynthesis and digital mammography in
women with dense breasts in screening setting
Studies comparing two groups of participants (N = 8)
All but two studies used single-reading. Six studies were
included in the analysis of CDR and were homogeneous
in reporting CDR (I2 = 0%). CDR was estimated to be
significantly higher when using DBT with or without
DM compared to DM alone (RR = 1.33, 95% CI 1.20–1.
47) (Fig. 3b). Seven studies reported recall rates with
high heterogeneity (I2 = 93%). Pooled estimate for these
studies showed a significant reduction in recall rate
when using DBT with or without DM compared to DM
alone (RR = 0.72, 95% CI 0.64–0.80) (Fig. 4a). Subgroup
analysis based on test definition showed consistently
reduced recall rates (RR = 0.59, 95% CI 0.52–0.67 for BI-
RADS 0 as recalled and RR = 0.84, 95% CI 0.81–0.87 for
other definitions). Subgroup analysis also reduced het-
erogeneity in subgroup estimates (I2: 62% and 37%,
respectively) (Additional file 3).
Table 1 Quality appraisal of included studies
DM digital mammography, DBT digital breast tomosynthesis
(1)This question is applicable for retrospective diagnostic study. (2) This question is applicable for studies reporting sensitivity and specificity
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Studies comparing within the same group of participants
(paired data) (N = 3)
These studies used DBTcombined with DM [16, 19] or DBT
alone [23], double-reading protocol and similar definitions
for recall. Pooled estimates from three studies showed im-
proved CDR when using DBT with DM compared to DM
alone, RR= 1.52, 95%CI 1.08–2.12 (Fig. 3c) with homogeneity
across studies (I2 = 0%). Using DBT with DM did not reduce
recall rate based on two studies (I2 = 76%). The pooled RR
was 1.12, 95% CI 0.76–1.63 (Fig. 4b). Subgroup analysis was
not performed due to a small number of studies.
Discussion
This systematic review identified 16 studies (5 diagnostic
and 11 screening studies) comparing accuracy measures,
such as CDR, recall rate, sensitivity and specificity, of
DBT and DM in women with dense breasts at mammog-
raphy. We found that in diagnostic studies, DBT with or
without DM improved CDR (RR = 1.12, 95% CI 1.01–1.
24) and sensitivity compared to DM alone (84%–89% vs
69%–86%) in women with dense breasts, whereas speci-
ficity did not increase when DBT was used (72–93% vs
57–94%). In the screening setting, CDR was improved
when using DBT with or without DM, in studies com-
paring within one study group (RR = 1.52, 95% CI 1.08–
2.12) or comparing two study groups of participants
(RR = 1.33, 95% CI 1.20–1.47). Recall rate was reduced
when using DBT compared to DM alone in screening
studies using two study groups (RR = 0.72, 95% CI 0.64–
0.80), though heterogeneity across studies was very high
Fig. 2 Forest plot and Summary receiver operating characteristic plot of DBT and DM in diagnostic setting
Phi et al. BMC Cancer  (2018) 18:380 Page 5 of 9
(I2 = 93%) and partially explained by the two different
definitions of outcome.
Almost all of the reviews in the literature comparing
DBT with DM in BC screening do not distinctly report on
women with dense breasts. One review, not restricted to
women with dense breasts, reported that DBT with DM in-
creased CDR with a RR of 1.29 (95% CI 1.16–1.43) (Yun et
al. [31]) which is comparable to our estimate. We identified
only two reviews reporting on women with dense breasts,
one was a quantitative rapid review and one was a narrative
review without analyses [14, 15]. The rapid review identified
eight studies comparing CDR and recall rate of DBT plus
DM to DM alone in women with dense breasts but was re-
stricted to screening studies. The rapid review reported a
significantly increased CDR when pooling studies compar-
ing within same group of participants (incremental cancer
detection per 1000 screens: 3.9, 95% CI 2.7–5.1) as well as
when pooling studies comparing two groups of participants
(incremental cancer detection per 1000 screens: 1.4, 95% CI
0.9–2.0) [14]. Although our results are generally in line with
these previous reviews, by performing a systematic search
and by considering both screening and diagnostic studies,
we were able to identify more data sources for the compari-
son of DBT with DM, and were also able to present data
on a broader range of outcomes (sensitivity and specificity
as well as CDR and recall rate) hence we extend on existing
reviews. In addition, we conducted quality assessment of
the included evidence which was not done in the other re-
views on this issue.
Studies included in our review were heterogeneous in
several aspects. Firstly, some studies included asymp-




Fig. 3 Cancer detection rate of DBT and DM in diagnostic and screening studies. a In diagnostic studies. b In screening studies using two study
groups. c In screening studies using one study group
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investigate the accuracy of DBT and DM in BC screen-
ing, some studies included women who were recalled
after screening [12, 17, 21, 30]. By doing so, they ob-
tained populations recalled to assessment which have
higher cancer rates than unselected asymptomatic popu-
lations. However, the results from the screening and
diagnostic settings had generally comparable findings.
Secondly, retrospective studies tended to perform single-
reading whereas the prospective studies performed
double-reading (reflecting screening practice in various
settings) which may increase CDRs in the latter. In the
two STORM trials, screen-reading results were based on
recall by either reader, making the recall rate of inte-
grated DM and DBT higher than DM in STORM-2 [16]
and non-significantly lower in STORM-1 [19]. Addition-
ally, all but one [23] screening study used DBT together
with DM while among five diagnostic studies two studies
used DBT as stand-alone modality [17, 30].
Another difference among studies was the outcome
definitions which may be contributing to some of the
observed heterogeneity. Studies performed in the United
States used the BI-RADS system for reporting recall
whereas the European studies used a simplified ‘recall or
no recall’ reporting for screen-readings. Amongst studies
using BI-RADS, different thresholds were used to define
recall or positive test. When analysing data for different
thresholds, the result of recall rate in screening studies
using two study groups remained significantly lower for
DBT compared to DM but the heterogeneity decreased.
Studies defining BI-RADS 0 as recall [22, 27, 29] showed
a larger decrease in recall rate than studies using a dif-
ferent definition (BI-RADS 0,3,4,5 [20] or BI-RADS 0,4,5
[25] or where unspecified [26, 28]). Among four diag-
nostic studies reporting sensitivity and specificity, one
study from the UK [21] used a lower threshold (BI-
RADS 3 instead of BI-RADS 4) and reported lower spe-
cificity than other diagnostic studies which may account
for more false positives.
The main limitation of the data used in our analysis is
that all but two screening studies [20, 23] used only a sin-
gle screening (likely to be first round) for DBT. When only
first DBT screening rounds are used [19, 24, 26–29], more
prevalent cases are usually detected, increasing CDR and
potentially exaggerating the contribution of DBT to
screen-detection measures. Another limitation is the short
temporal perspective in all these studies: because of the
recent introduction of DBT, the lack of long follow-up
makes it impossible to assess whether the improved CDR
and sensitivity of DBT screening further reduces BC mor-
tality through screening compared to screening with DM
alone. The retrospective studies had one major limitation
in that they used two study groups (DM group versus
DBT group) which were not randomly assigned to screen-
ing modalities. The study groups were from different time
periods (or services) and in the DBT implementation
phase, or due to the limit of DBT availability, there may
a
b
Fig. 4 Recall rate of DBT and DM in screening studies. a Studies used two study groups. b Studies used one study group
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have been selection to DBT screening and hence potential
bias. In those studies, DBT groups were more likely to in-
clude women with dense breasts and family history indi-
cating high cancer rate. The incremental value of DBT in
those studies may be partially due to possible selection bias.
Finally, in order to be able to compute the results, we made
an assumption of independent screens, which might not be
the case in the few studies that included more than one
screening round [20, 25] or where study populations might
overlap [16, 19]. However, estimates from those studies
were similar to the other studies, thus we do not foresee
that this assumption affected our reported findings.
We performed a systematic review to summarize current
evidence on the use of DBT in BC screening and diagnosis
specifically in women with dense breasts on mammog-
raphy. We identified and systematically examined data for
women with dense breasts from 16 eligible studies to report
the most extensive review so far on the accuracy of DBT in
women with dense breasts. Moreover, this is the first review
assessing the quality of evidence and bias in the studies on
DBT in women with dense breasts.
Conclusion
We found that in both the screening and diagnostic set-
tings, DBT improved CDR (versus DM) in women with
dense breasts. In the diagnostic setting, using DBT with or
without DM increased sensitivity but did not change spe-
cificity. There was a significant reduction in recall rate
when using DBT with DM (versus DM) in retrospective
screening studies comparing between two study groups,
although heterogeneity across studies was relatively high.
A small number of prospective studies conducted in orga-
nized screening programs did not show reduced recall
from using DBT. Improved CDR and reduced recall rate
from DBT may imply a more effective screening test or
diagnostic work-up for women with dense breasts. How-
ever, the critical issue is that more studies with longer
follow-up and more screening rounds are necessary to
draw definite conclusions on whether this improvement
in cancer detection has an impact on interval cancer rates
and potentially on BC mortality.
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